Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

Stanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) yesterday and set a price ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – Research Report), ...

Israeli drug manufacturer Teva Pharmaceutical Industries has resumed the deliveries of the scarce epilepsy drug Finlepsin ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.